The Infusion of Ex Vivo, Interleukin-15 and -21-Activated Donor NK Cells after Haploidentical HCT in High-Risk AML and MDS Patients—a Randomized Trial

Clinical effect of donor-derived natural killer cell infusion after HLA-haploidentical hematopoietic cell transplantation (HCT) was evaluated in high-risk myeloid malignancy in Phase 2, randomized trial.